Barriers to biosimilar utilization in the United States

Am J Health Syst Pharm. 2020 Nov 16;77(23):2006-2014. doi: 10.1093/ajhp/zxaa297.

Authors

Stacy Elder Dalpoas¹, Mariana Socal², Celia Proctor³, Kenneth M Shermock³

Affiliations

¹ Department of Pharmacy, Johns Hopkins Bayview Medical Center, Baltimore, MD.
² Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
³ Department of Pharmacy, Johns Hopkins Health System, Baltimore, MD.

PMID: 33091103
DOI: 10.1093/ajhp/zxaa297

No abstract available

MeSH terms

Biological Products / administration & dosage*
Biosimilar Pharmaceuticals / therapeutic use*
Drug Approval / statistics & numerical data*
Humans
United States
United States Food and Drug Administration

Substances

Biological Products
Biosimilar Pharmaceuticals